These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6863539)

  • 1. Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.
    Penno MB; Vesell ES
    J Clin Invest; 1983 Jun; 71(6):1698-709. PubMed ID: 6863539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new polymorphism of hepatic drug oxidation in humans: family studies of antipyrine metabolites.
    Vesell ES; Penno MB
    Fed Proc; 1984 May; 43(8):2342-7. PubMed ID: 6714443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphism of theophylline metabolism in man.
    Miller CA; Slusher LB; Vesell ES
    J Clin Invest; 1985 May; 75(5):1415-25. PubMed ID: 4039734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new polymorphism of hepatic drug oxidation in man: family studies on rates of formation of antipyrine metabolites.
    Vessell ES; Penno MB
    Biochem Soc Trans; 1984 Feb; 12(1):74-8. PubMed ID: 6705993
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins.
    Penno MB; Dvorchik BH; Vesell ES
    Proc Natl Acad Sci U S A; 1981 Aug; 78(8):5193-6. PubMed ID: 6946467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cimetidine-induced reduction in gastrointestinal absorption of antipyrine and rate constants for formation of its metabolites.
    Slusher LB; Vesell ES
    Clin Pharmacol Ther; 1984 May; 35(5):568-75. PubMed ID: 6713770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elimination studies of antipyrine and its metabolites in healthy Saudi Arabians.
    Ali HA; el-Yazigi A; Sieck JO; Døssing M; Saour J; Raines DA; Ernst P
    Hum Exp Toxicol; 1994 Oct; 13(10):658-62. PubMed ID: 7826682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipyrine pharmacokinetics and urinary excretion in female horses.
    Dyke TM; Sams RA; Hinchcliff KW
    Am J Vet Res; 1998 Mar; 59(3):280-5. PubMed ID: 9522945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of dioxins on antipyrine metabolism in firefighters.
    Chernyak YI; Merinova AP; Shelepchikov AA; Kolesnikov SI; Grassman JA
    Toxicol Lett; 2016 May; 250-251():35-41. PubMed ID: 27067104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sources of interindividual variations in acetaminophen and antipyrine metabolism.
    Nash RM; Stein L; Penno MB; Passananti GT; Vesell ES
    Clin Pharmacol Ther; 1984 Oct; 36(4):417-30. PubMed ID: 6541104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of methods to identify sources of interindividual pharmacokinetic variations.
    Vesell ES; Penno MB
    Clin Pharmacokinet; 1983; 8(5):378-409. PubMed ID: 6194927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.
    Boobis AR; Brodie MJ; Kahn GC; Toverud EL; Blair IA; Murray S; Davies DS
    Br J Clin Pharmacol; 1981 Dec; 12(6):771-7. PubMed ID: 7340879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of mefloquine in man: lack of effect of mefloquine on antipyrine metabolism.
    Rivière JH; Back DJ; Breckenridge AM; Howells RE
    Br J Clin Pharmacol; 1985 Nov; 20(5):469-74. PubMed ID: 3878153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between the in vivo metabolism of hexobarbital and antipyrine in rats with a portacaval shunt.
    van der Graaff M; Vermeulen NP; Joeres RP; Breimer DD
    Pharmacology; 1984; 29(2):99-109. PubMed ID: 6473507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of verapamil on antipyrine pharmacokinetics and metabolism in man.
    Bach D; Blevins R; Kerner N; Rubenfire M; Edwards DJ
    Br J Clin Pharmacol; 1986 Jun; 21(6):655-9. PubMed ID: 3741715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
    Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
    Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of antipyrine metabolite formation. Steady state studies with cimetidine and metyrapone in rats.
    Shaw PN; Tseti J; Warburton S; Adedoyin A; Houston JB
    Drug Metab Dispos; 1986; 14(2):271-6. PubMed ID: 2870906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.
    Buchanan N; Davis M; Danhof M; Breimer DD
    Br J Clin Pharmacol; 1980 Oct; 10(4):363-8. PubMed ID: 7448107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diltiazem treatment impairs hepatic drug oxidation: studies of antipyrine.
    Carrum G; Egan JM; Abernethy DR
    Clin Pharmacol Ther; 1986 Aug; 40(2):140-3. PubMed ID: 3731677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of antipyrine and its metabolites in interferon treated hepatitis C.
    Sieck JO; el-Yazigi A; Ali H; Døssing M; Saour J; Raines DA; Ernst P
    Hum Exp Toxicol; 1994 Sep; 13(9):598-601. PubMed ID: 7986571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.